Clinical significance of postoperative CA-125 level after primary cytoreductive surgery in ovarian cancer To the editor: The current study is meaningful in that the decline in serum CA125 levels after primary cytoreductive surgery may affect progressionfree survival (PFS) in patients with epithelial ovarian cancer (EOC). Moreover, similar studies have also shown that the serum CA125 level may be a prognostic factor for the prediction of survival in patients with EOC although the time to evaluate serum CA125 levels was different. 13 However, some questions should be resolved for understanding the role of serum CA125 levels in EOC. Firstly, histological type of EOC may affect serum CA125 levels. Especially, serum CA125 levels are known to be lower in clear cell or mucinous carcinoma than in serous adenocarcinoma. 4 Thus, a higher rate of nonserous type ovarian cancer may affect serum CA125 levels and interrupt the reflection of tumor burden by serum CA125 levels. Thus, the rate of nonserous type ovarian cancer might affect no correlation between postoperative decline in serum CA125 levels and residual disease. Secondly, various types of chemotherapeutic regimen may affect response and survival in patients with EOC. Although all patients received platinum based chemotherapy in the current study, the authors have not shown how many patients received taxane and platinum based chemotherapy. In some studies of Gynecologic Oncology Group (GOG), taxane and platinumbased chemotherapy has been reported to be the most efficient for the treatment of EOC. 5, 6 Thus, if there were different chemotherapeutic regimens in the current study, PFS might be influenced by type of chemotherapeutic regimen as well as serum CA125 levels. Thirdly, retrospective design may affect the results by some bias.
Conclusively, serum CA125 levels may be helpful for the prediction of clinical outcomes in patients with EOC who received staging laparotomy followed by adjuvant chemotherapy. However, prospective clinical trials by controlling some bias such as various histological types and different types of chemotherapeutic regimen are needed for evaluating the definite role of serum CA125 levels.
In reply:
We are grateful to Dr. Kim for their interest in our article. In our study, we showed that postoperative decline of CA-125 may be associated with progression free survival in patients with advanced stage ovarian cancer.
First, Dr. Kim said that non-serous malignant tumors should be excluded from the study group. But practically speaking, there is no better tumor maker for malignant mucinous tumors other than CA-125, and indeed there are many other articles in the literature that have included CA-125 measurements in patients with malignant tumors other than serous types including mucinous ones. 1-3 Second, we agree that platinum based chemotherapy without paclitaxel is an acceptable choice of treatment but may be not the best regimen. In our study, the number of patients who received chemotherapy without paclitaxel was 17 among 42 patients in the <75% decline group, and it was 14 among 39 of the ≥75% group, and there was no statistical difference (p=0.819).
There is substantial literature concerning CA-125 levels and ovarian cancer. Unfortunately, there have been no prospective
